HRD score analysis was used to measure HRD-related PCa risks and to compare germline mutations in BRCA2, ATM, and CHEK2 in three patient cohorts from the Cancer Genome Atlas, PROGENE, and Johns Hopkins University, with the highest HRD score being in BRCA2 cases [73]. This evidence concerns the gene BRCA2 and posterior cortical atrophy.